An evaluation designedto be believed.
No single proponent can legitimately establish a clinical standard. The evaluation is independent by design, and it publishes null and negative findings alongside favorable ones.
Prospective, prespecified, independently controlled.
At minimum, the pilot uses a prospective pre/post design with repeated measures, blinded or independent scoring where feasible, and a prespecified analysis plan. If enough agencies participate, a phased or stepped-wedge rollout strengthens inference by allowing later-starting groups to serve as temporary comparators. The independent evaluator — not the program — controls the analysis and reports the limitations.
The primary endpoint is an observable readiness measure directly affected by training, such as time to effective hemorrhage control in a standardized scenario, rather than mortality. Secondary endpoints address coordination, retention, data quality, and implementation feasibility. Patient outcomes may be explored only when legal authority, data quality, sample size, and ethics review support it.
Primary endpoint · Hemorrhage-control intervalSuccess is defined before data collection begins.
Conditions that must hold
- All participating institutions sign governance, medical-direction, data-use, and exercise agreements before training begins.
- The crosswalk conflicts with no controlling law, scope of practice, medical direction, or current agency protocol.
- Primary measures demonstrate acceptable inter-rater reliability and data completeness before any outcome comparison.
- At least one prespecified primary readiness endpoint improves measurably, with no deterioration in safety endpoints.
Conditions on what happens next
- Retention testing determines whether gains persist; recertification intervals are set to measured decay, not assumed decay.
- Independent evaluation finds the package feasible and states the conditions required for replication.
- No expansion occurs solely because the pilot was completed. Expansion follows the evidence or does not happen.
Stated directly, not implied away.
T-EMRP has not demonstrated reliability across sites, persistence of training gains, cost-effectiveness, acceptability to U.S. agencies, or any effect on patient outcomes. A pilot sample may be too small for mortality analysis. Local law, scope of practice, labor rules, records law, and medical direction vary by jurisdiction. Any composite readiness index remains a hypothesis until construct validity, weighting, sensitivity, and fairness are demonstrated.
Publication commitment
The evaluation publishes positive, negative, and null findings. A partner institution should hold the program to this commitment.